| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
The Fifth Department of Oncology and the Department of Thoracic Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka 530-8480 [N. I., T. T., N. H., M. M.], and The First Department of Surgery, Nara Medical University, Nara 634-8522 [N. I., Y. N., M. S., H. K.], Japan
Purpose: We previously established a novel murine monoclonal antibody(MH8-11) that recognized aminopeptidase N (APN)/cluster of differentiation antigen 13 (CD13). This monoclonal antibody inhibited human umbilical vein endothelial cells migration and capillary-like tube formation of human umbilical vein endothelial cells on Matrigel. In this study, we investigated the expression of APN/CD13 and the intratumor microvessel density (IMD) as the number of microvessel counts in 50 patients with pancreatic carcinoma.
Experimental Design: We investigated APN/CD13 gene expression using the reverse transcriptase-PCR. We also used immunohistochemistry with MH8-11 to investigate APN/CD13 protein expression. Moreover, we investigated the relationship between APN/CD13 expression and tumor angiogenesis by measuring the IMD.
Results: APN/CD13 gene expression detected by reverse transcriptase-PCR was positive in 50.0% (25 of 50) of the tumors, and APN/CD13 protein positive was detected by immunohistochemistry in 48.0% (24 of 50). APN/CD13 gene expression agreed well with the immunohistochemical findings (90.0% concordance). APN/CD13 was also significantly associated with an increase of the IMD (r = 0.71, P = 0.0003). However, APN/CD13 expression was not associated with various prognostic factors. The median survival time of patients with APN/CD13 expression was significantly shorter than that of patients without APN/CD13 expression (P = 0.009), and multivariate analysis showed that the APN/CD13 status was a significant independent factor (P = 0.016).
Conclusions: Our data suggest that APN/CD13 may be a new prognostic marker for patients with pancreatic carcinoma and may have a relationship with the angiogenesis for this cancer.
This article has been cited by other articles:
|
|
 |
|
  J. Cai, O. Kehoe, G. M. Smith, P. Hykin, and M. E. Boulton The Angiopoietin/Tie-2 System Regulates Pericyte Survival and Recruitment in Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2163 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nomi, M. Sho, T. Akahori, K. Hamada, A. Kubo, H. Kanehiro, S. Nakamura, K. Enomoto, H. Yagita, M. Azuma, et al. Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2151 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tokuhara, N. Hattori, H. Ishida, T. Hirai, M. Higashiyama, K. Kodama, and M. Miyake Clinical Significance of Aminopeptidase N in Non-Small Cell Lung Cancer. Clin. Cancer Res., July 1, 2006; 12(13): 3971 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gronborg, T. Z. Kristiansen, A. Iwahori, R. Chang, R. Reddy, N. Sato, H. Molina, O. N. Jensen, R. H. Hruban, M. G. Goggins, et al. Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach Mol. Cell. Proteomics, January 1, 2006; 5(1): 157 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Murakami, A. Yokoyama, K. Kondo, S. Nakanishi, N. Kohno, and M. Miyake Circulating Aminopeptidase N/CD13 Is an Independent Prognostic Factor in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2005; 11(24): 8674 - 8679. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
